Literature DB >> 7708068

Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus.

A S Krolewski1, L M Laffel, M Krolewski, M Quinn, J H Warram.   

Abstract

BACKGROUND: The risk of microalbuminuria in patients with insulin-dependent diabetes mellitus (IDDM) is thought to depend on the degree of hyperglycemia, but the relation between the degree of hyperglycemia and urinary albumin excretion has not been defined.
METHODS: We measured urinary albumin excretion in three random urine samples obtained at least one month apart from 1613 patients with IDDM. Microalbuminuria or overt albuminuria was considered to be present if the ratio of albumin (in micrograms) to creatinine (in milligrams) was 17 to 299 or > or = 300, respectively, for men and 25 to 299 or > or = 300, respectively, for women. Measurements of glycosylated hemoglobin (hemoglobin A1) obtained up to four years before the urine testing were used as an index of hyperglycemia. Twelve percent of the patients had overt albuminuria and were excluded from subsequent analyses.
RESULTS: The prevalence of microalbuminuria was 18 percent in patients with IDDM. It increased with increasing postpubertal duration of diabetes and, within each six-year interval of disease duration, it increased nonlinearly with the hemoglobin A1 value. For hemoglobin A1 values below 10.1 percent, the slope of the relation was almost flat, whereas for values above 10.1 percent, the prevalence of microalbuminuria rose steeply (P < 0.001). For example, as the hemoglobin A1 value increased from 8.1 to 10.1 percent, the odds of microalbuminuria increased by a factor of 1.3, but as the value increased from 10.1 to 12.1 percent, the odds were increased by a factor of 2.4.
CONCLUSIONS: The risk of microalbuminuria in patients with IDDM increases abruptly above a hemoglobin A1 value of 10.1 percent (equivalent to a hemoglobin A1c value of 8.1 percent), suggesting that efforts to reduce the frequency of diabetic nephropathy should be focused on reducing hemoglobin A1 values that are above this threshold.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7708068     DOI: 10.1056/NEJM199505113321902

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  66 in total

Review 1.  Is it possible to predict diabetic kidney disease?

Authors:  S M Thomas; G C Viberti
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256

2.  Revisiting the oral glucose tolerance test criterion for the diagnosis of diabetes.

Authors:  M B Davidson; D L Schriger; A L Peters; B Lorber
Journal:  J Gen Intern Med       Date:  2000-08       Impact factor: 5.128

3.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Authors:  I M Stratton; A I Adler; H A Neil; D R Matthews; S E Manley; C A Cull; D Hadden; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

4.  Genetic variation in the matrix metalloproteinase genes and diabetic nephropathy in type 1 diabetes.

Authors:  Masahiko Kure; Marcus G Pezzolesi; G David Poznik; Pisut Katavetin; Jan Skupien; Jonathon S Dunn; Josyf C Mychaleckyj; James H Warram; Andrzej S Krolewski
Journal:  Mol Genet Metab       Date:  2011-01-14       Impact factor: 4.797

5.  Effective antihypertensive strategies for high-risk patients with diabetic nephropathy.

Authors:  Peter Noel Van Buren; Beverley Adams-Huet; Robert Daniel Toto
Journal:  J Investig Med       Date:  2010-12       Impact factor: 2.895

Review 6.  Microalbuminuria in diabetes mellitus.

Authors:  Sheldon W Tobe; Philip Alan McFarlane; David Malcolm Naimark
Journal:  CMAJ       Date:  2002-09-03       Impact factor: 8.262

7.  Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes.

Authors:  Monika A Niewczas; Linda H Ficociello; Amanda C Johnson; William Walker; Elizabeth T Rosolowsky; Bijan Roshan; James H Warram; Andrzej S Krolewski
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 8.237

8.  Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial.

Authors:  Richard E Gilbert; Johannes F E Mann; Markolf Hanefeld; Giatgen Spinas; Jackie Bosch; Salim Yusuf; Hertzel C Gerstein
Journal:  Diabetologia       Date:  2014-04-26       Impact factor: 10.122

Review 9.  The relationship between glucose control and the development and progression of diabetic nephropathy.

Authors:  Carrie A Phillips; Mark E Molitch
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

10.  Relationship among psychopathological dimensions, coping mechanisms, and glycemic control in a Croatian sample of adolescents with diabetes mellitus type 1.

Authors:  Milena Skocić; Vlasta Rudan; Lovorka Brajković; Darko Marcinko
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-09-24       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.